Longitudinal Effects of Diabetes-Associated Variation in TCF7L2 on Glucagon and Insulin Secretion in Non-Diabetic Humans

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 16-010317
    Sponsor Protocol Number: 16-010317

About this study

The goal of this study is to determine the role of postprandial glucagon suppression and insulin secretion in the progression of glucose intolerance in people with diabetes-associated variation in TCF7L2.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Individuals who previously underwent a 2 hour, 7-sample oral glucose tolerance test as part of IRB# 348-05 (n:190); IRB# 07-005203 (n:187) and IRB# 11-007525 (n:135) and on who we have minimal model indices of insulin secretion and insulin action. We propose to recruit subjects from these cohorts who are homozygous for the disease-associated allele (T) at rs7903146 or homozygous for the disease-protecting allele (C).

Exclusion Criteria:

  • No known active systemic illness
  • Be taking any medication that could affect glucose metabolism
  • No history of abdominal surgery (other than appendectomy or tubal ligation).
  • Subjects with a fasting blood glucose >126 mg/dL

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Open for enrollment

Contact information:

Paula Giesler R.N.

(507)255-8345

Giesler.Paula@mayo.edu

.
CLS-20307912

Mayo Clinic Footer